Endothelium-targeted gene and cell-based therapies for cardiovascular disease

Luis G. Melo, Massimiliano Gnecchi, Alok S. Pachori, Deling Kong, Kai Wang, Xiaoli Liu, Richard E. Pratt, Victor J. Dzau

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. "Proof-of-concept" for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized.

Original languageEnglish
Pages (from-to)1761-1774
Number of pages14
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume24
Issue number10
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Cell- and Tissue-Based Therapy
Endothelium
Cardiovascular Diseases
Genes
Blood Vessel Prosthesis
Bioengineering
Tropism
Vascular Endothelium
Reperfusion Injury
Transgenes
Thoracic Surgery
Blood Vessels
Atherosclerosis
Chronic Disease
Therapeutics
Animal Models
Arteries
Myocardial Infarction
Hypertension
Technology

Keywords

  • Endothelial progenitor cells
  • Endothelial-specific expression
  • Gene therapy
  • Targeting
  • Viral vectors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Endothelium-targeted gene and cell-based therapies for cardiovascular disease. / Melo, Luis G.; Gnecchi, Massimiliano; Pachori, Alok S.; Kong, Deling; Wang, Kai; Liu, Xiaoli; Pratt, Richard E.; Dzau, Victor J.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 24, No. 10, 10.2004, p. 1761-1774.

Research output: Contribution to journalArticle

Melo, Luis G. ; Gnecchi, Massimiliano ; Pachori, Alok S. ; Kong, Deling ; Wang, Kai ; Liu, Xiaoli ; Pratt, Richard E. ; Dzau, Victor J. / Endothelium-targeted gene and cell-based therapies for cardiovascular disease. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2004 ; Vol. 24, No. 10. pp. 1761-1774.
@article{abd858489c59406aac2c30348fd4b6d2,
title = "Endothelium-targeted gene and cell-based therapies for cardiovascular disease",
abstract = "Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. {"}Proof-of-concept{"} for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized.",
keywords = "Endothelial progenitor cells, Endothelial-specific expression, Gene therapy, Targeting, Viral vectors",
author = "Melo, {Luis G.} and Massimiliano Gnecchi and Pachori, {Alok S.} and Deling Kong and Kai Wang and Xiaoli Liu and Pratt, {Richard E.} and Dzau, {Victor J.}",
year = "2004",
month = "10",
doi = "10.1161/01.ATV.0000142363.15113.88",
language = "English",
volume = "24",
pages = "1761--1774",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Endothelium-targeted gene and cell-based therapies for cardiovascular disease

AU - Melo, Luis G.

AU - Gnecchi, Massimiliano

AU - Pachori, Alok S.

AU - Kong, Deling

AU - Wang, Kai

AU - Liu, Xiaoli

AU - Pratt, Richard E.

AU - Dzau, Victor J.

PY - 2004/10

Y1 - 2004/10

N2 - Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. "Proof-of-concept" for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized.

AB - Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. "Proof-of-concept" for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized.

KW - Endothelial progenitor cells

KW - Endothelial-specific expression

KW - Gene therapy

KW - Targeting

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=5344271164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5344271164&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.0000142363.15113.88

DO - 10.1161/01.ATV.0000142363.15113.88

M3 - Article

VL - 24

SP - 1761

EP - 1774

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 10

ER -